ストックスクリーナーアプリを入手
113.18
0.79%
0.89
アフターアワーズ：
113.50
0.32
+0.28%
Gilead Sciences Inc (GILD) 最新ニュース
Why is Gilead Sciences Inc. stock attracting strong analyst attentionBuild wealth steadily with proven methods - jammulinksnews.com
Why Gilead Sciences Stock Just Popped - AOL.com
Gilead Sciences gets USFDA nod for new Biktarvy indication for people with HIV who are treatment... - Medical Dialogues
Pheton Holdings Dismisses Rumors Of Acquisition By Gilead, But Retail’s Extremely Optimistic - Stocktwits
Pheton Holdings Ltd Issues Statements Addressing Recent Market Activity and Misleading Rumors - Stock Titan
Gilead Employees Give Back During Month of Service - Gilead Sciences
Trump targets Genentech, Gilead in 'most favored nation' drug-pricing decreeSan Francisco Business Times - The Business Journals
Gilead and Arcus Advance Promising Colorectal Cancer Study - TipRanks
Two Shots A Year: How A New HIV Drug Is Tackling Stigma And Saving Lives - Forbes
Gilead Sciences Advances Pediatric Hepatitis B Treatment with TAF Study Update - TipRanks
Gilead’s Promising Phase 3 Study in Metastatic Breast Cancer: A Potential Game Changer - TipRanks
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Are Wall Street Analysts Bullish On Gilead Sciences Stock? - Barchart.com
How Dr. Toyin Nwafor of Gilead targets HIV disparities - Rolling Out
What data driven models say about Gilead Sciences Inc.’s futureChart Breakout Buy Signal Detection Confirmed - metal.it
Gilead and Arcus Advance Cancer Treatment Study with AB308 and Zimberelimab - TipRanks
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now? - MSN
Gilead files covid 19 remdesivir actions against Chinese military research institute - IAM Patent
[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
NY Judge Faces Recusal Request Over Gilead Stock Holdings - Law360
Gilead Sciences’ TAF Study in Children with Hepatitis B: An Update - TipRanks
BMO says WSJ report on RFK potential headwind for Gilead - Yahoo Finance
AbbVie, Gilead and GSK back World Hepatitis Day, seeking to tackle stigma to drive elimination - Fierce Pharma
Gilead Sciences’ Strategic Positioning and Growth Prospects in the HIV Prevention Market Justify Buy Rating - TipRanks
Gilead price collects profitsForecast today29-07-2025 - Economies.com
Integrase Inhibitors Market Growth and Future Scope 2025-2032 | - openPR.com
Order Flow Trends Show Accumulation in Gilead Sciences Inc.Long Hold Safe Return Strategy Reviewed - metal.it
What are the technical indicators suggesting about Gilead Sciences Inc.Post Market Planner That Work - jammulinksnews.com
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Why Gilead Sciences Stock Slipped Today - AOL.com
Gilead down as analysts see RFK Jr. preventative task force action negatively - Seeking Alpha
Gilead Sciences stock falls amid reports of preventive health panel dismissal - Investing.com
BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive - Stocktwits
Is Gilead Sciences Inc. stock overvalued or undervaluedConsistent double returns - jammulinksnews.com
Gilead Sciences Earns Membership In 95-Plus Composite Rating Club - Investor's Business Daily
Citi Maintains a Buy Rating on Gilead Sciences (GILD) - MSN
TD Cowen Remains Bullish on Gilead Sciences (GILD) - Insider Monkey
What is Gilead Sciences Inc. company’s growth strategyFree Predictions - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc.GILD - PR Newswire
Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet? - simplywall.st
Lenacapavir: After FDA approval, HIV pre-exposure prophylaxis injectable moving closer to EU approval - The Hindu
Gilead Sciences Stock Surges Amid Promising Trials - TipRanks
10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey
European Medicines Agency Recommends Lenacapavir (Yeztugo) Injectable PrEP for HIV Prevention - Contagion Live
Why Gilead Sciences (GILD) Stock Is Up Today - Yahoo Finance
Gilead Sciences (GILD) Receives Upgraded Rating from Needham | G - GuruFocus
Gilead Sciences’ Latest Study: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three - insights.citeline.com
EU regulator backs Gilead's twice-yearly injection for HIV prevention - Reuters
Gilead upgraded to Buy at Needham on new HIV drug - MSN
Gilead Sciences (GILD) Gains Upgrade Amid Promising HIV Drug Outlook - GuruFocus
What analysts say about Gilead Sciences Inc. stockFree Stock Market Beginners Guide - PrintWeekIndia
Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance
Analyst recommendations: Thermo Fisher Scientific, Intel, Honeywell International, Union Pacific, Gilead Sciences... - MarketScreener
This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
EU regulator backs Gilead’s twice-yearly injection for HIV prevention - PharmaLive
Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet - Stocktwits
Gilead wins EU backing for twice-yearly HIV PrEP therapy - Seeking Alpha
0.86%
大文字化:
|
ボリューム (24 時間):